

Silvia C Formenti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6332820/silvia-c-formenti-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

153
papers

17,364
citations

56
h-index

131
g-index

171
ext. papers

21,515
ext. citations

8.7
avg, IF

7.13
L-index

#	Paper	IF	Citations
153	Mobile mammography in New York City: analysis of 32,350 women utilizing a screening mammogram program.. <i>Npj Breast Cancer</i> , 2022 , 8, 14	7.8	
152	Natural history of lower urinary tract symptoms among men undergoing stereotactic body radiation therapy for prostate cancer with and without a Rectal Hydrogel Spacer.. <i>World Journal of Urology</i> , 2022 , 1	4	0
151	Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.. <i>Lancet Oncology, The</i> , 2022 , 23, e156	21.7	0
150	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy.. <i>Breast</i> , 2022 , 63, 123-139	3.6	3
149	Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. <i>Nature Reviews Clinical Oncology</i> , 2021 ,	19.4	15
148	733 Immunological mechanisms of resistance to CDK4/CDK6 inhibitors in breast cancer 2021 , 9, A763-A763		
147	285 Breaking through the resistance of breast cancer to immune checkpoint blockers in a unique mouse model of HR+ disease 2021 , 9, A309-A309		
146	Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva 2021 ,		14
145	Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	38
144	Liver Metastasis Irradiation Can Restore Immunotherapeutic Responsiveness. <i>Trends in Immunology</i> , 2021 , 42, 275-277	14.4	
143	Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 824-835	21.7	45
142	Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Oncologist</i> , 2021 , 26, e1508-e1513	5.7	5
141	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). <i>Journal of Translational Medicine</i> , 2021 , 19, 238	8.5	1
140	Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. <i>Pathogens and Immunity</i> , 2021 , 6, 116-134	4.9	47
139	Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 110, 35-52	4	31
138	Activin A Promotes Regulatory T-cell-Mediated Immunosuppression in Irradiated Breast Cancer. <i>Cancer Immunology Research</i> , 2021 , 9, 89-102	12.5	20
137	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). <i>Journal of Translational Medicine</i> , 2021 , 19, 13	8.5	1

136	Development of a Model to Estimate the Association Between Delay in Cancer Treatment and Local Tumor Control and Risk of Metastases. <i>JAMA Network Open</i> , 2021 , 4, e2034065	10.4	3
135	Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1855-1863	12.9	17
134	3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine. <i>Nature Communications</i> , 2021 , 12, 4447	17.4	9
133	Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals. <i>JCI Insight</i> , 2021 , 6,	9.9	4
132	The Impact of Radiation Therapy on Innate and Adaptive Tumor Immunity. <i>Seminars in Radiation Oncology</i> , 2020 , 30, 139-144	5.5	14
131	Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2020 , 8, 1054-1063	12.5	10
130	Radiation-induced Adaptive Response: New Potential for Cancer Treatment. <i>Clinical Cancer Research</i> , 2020 , 26, 5781-5790	12.9	20
129	The abscopal effect 67 years later: from a side story to center stage. <i>British Journal of Radiology</i> , 2020 , 93, 20200042	3.4	36
128	CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection. <i>Cancer Immunology Research</i> , 2020 , 8, 465-478	12.5	46
127	PTEN as a Guardian of the Genome: Pathways and Targets. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020 , 10,	5.4	8
126	Cancer and COVID-19 - potentially deleterious effects of delaying radiotherapy. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 332-334	19.4	53
125	Immunomodulation by anticancer cell cycle inhibitors. <i>Nature Reviews Immunology</i> , 2020 , 20, 669-679	36.5	43
124	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death 2020 , 8,		233
123	First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2020 , 26, 1025-1033	12.9	26
122	Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?. <i>Radiation Research</i> , 2020 , 194, 452-464	3.1	24
121	Synergy of Immunotherapy and Radiosurgery 2020 , 355-369		
120	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020 , 11, 3819	17.4	41
119	Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. <i>Nature Immunology</i> , 2020 , 21, 1160-1171	19.1	94

118	Radiation Therapy and the In Situ Vaccination Approach. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 108, 891-898	4	15
117	Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade. <i>Onc Immunology</i> , 2020 , 9, 1830524	7.2	17
116	PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. <i>Gynecologic Oncology</i> , 2020 , 159, 322-328	4.9	15
115	Harnessing radiation to improve immunotherapy: better with particles?. <i>British Journal of Radiology</i> , 2020 , 93, 20190224	3.4	31
114	Radiosurgery and Immunotherapy in the Treatment of Brain Metastases. <i>World Neurosurgery</i> , 2019 , 130, 615-622	2.1	7
113	Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality. <i>International Journal of Radiation Biology</i> , 2019 , 95, 936-939	2.9	40
112	Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. <i>Genome Medicine</i> , 2019 , 11, 40	14.4	94
111	Shaping the Path for a Global Oncology Academic Career. <i>JAMA Oncology</i> , 2019 , 5, 931-932	13.4	6
110	Enhancing Career Paths for Tomorrow's Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 52-63	4	13
109	Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients 2019 , 7, 177		22
108	Analysis of Pathologic Complete Response 10 Weeks After Radiotherapy-A Radiobiological Sin. <i>JAMA Oncology</i> , 2019 , 5, 1365	13.4	
107	Preoperative radiotherapy for high-risk prostate cancer (PORT-PC) trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS137-TPS137	2.2	
106	Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial 2019 , 7, 318		8
105	Estimating child mortality associated with maternal mortality from breast and cervical cancer. <i>Cancer</i> , 2019 , 125, 109-117	6.4	14
104	Focal Irradiation and Systemic TGF β Blockade in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 2493-2504	12.9	130
103	Radiotherapy and checkpoint inhibitors: a winning new combination?. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918768240	5.4	58
102	Qualitative Assessment of Academic Radiation Oncology Department Chairs' Insights on Diversity, Equity, and Inclusion: Progress, Challenges, and Future Aspirations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 30-45	4	19
101	Using immunotherapy to boost the abscopal effect. <i>Nature Reviews Cancer</i> , 2018 , 18, 313-322	31.3	502

100 Synergy Between Radiotherapy and Immunotherapy **2018**, 507-524

99	Integration of radiation and immunotherapy in breast cancer - Treatment implications. <i>Breast</i> , 2018 , 38, 66-74	3.6	26
98	Hypofractionated Whole-Breast Irradiation in Women Less Than 50 Years Old Treated on 4 Prospective Protocols. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 1159-1167 ⁴		9
97	Dual Transforming Growth Factor- β and Programmed Death-1 Blockade: A Strategy for Immune-Excluded Tumors?. <i>Trends in Immunology</i> , 2018 , 39, 435-437	14.4	25
96	Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers. <i>Clinical Cancer Research</i> , 2018 , 24, 259-265	12.9	102
95	Radiation-Induced Chromosomal Aberrations and Immunotherapy: Micronuclei, Cytosolic DNA, and Interferon-Production Pathway. <i>Frontiers in Oncology</i> , 2018 , 8, 192	5.3	58
94	Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs. <i>Cancer Immunology Research</i> , 2018 , 6, 910-920	12.5	145
93	Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells. <i>Cancer Immunology Research</i> , 2018 , 6, 139-150	12.5	119
92	Understanding Responses to Stereotactic Body Radiotherapy and Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2661-2662	2.2	9
91	Radiotherapy induces responses of lung cancer to CTLA-4 blockade. <i>Nature Medicine</i> , 2018 , 24, 1845-1851	10.5	379
90	Introduction to the special edition on immunotherapy and radiation oncology. <i>Advances in Radiation Oncology</i> , 2018 , 3, 484-485	3.3	1
89	Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation. <i>Advances in Radiation Oncology</i> , 2018 , 3, 486-493	3.3	34
88	Cytosolic DNA Sensing in Organismal Tumor Control. <i>Cancer Cell</i> , 2018 , 34, 361-378	24.3	109
87	The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 5792-5806	12.9	121
86	Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer. <i>OncImmunology</i> , 2017 , 6, e1274479	7.2	8
85	Combining Radiotherapy and Immunotherapy. <i>Cancer Treatment and Research</i> , 2017 , 1-20	3.5	1
84	TREX1 dictates the immune fate of irradiated cancer cells. <i>OncImmunology</i> , 2017 , 6, e1339857	7.2	59
83	DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. <i>Nature Communications</i> , 2017 , 8, 15618	17.4	770

82	Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 895-903	21.7	577
81	PTEN at the interface of immune tolerance and tumor suppression. <i>Frontiers in Biology</i> , 2017 , 12, 163-174		16
80	Trial watch: Immune checkpoint blockers for cancer therapy. <i>OncolImmunology</i> , 2017 , 6, e1373237	7.2	53
79	Barriers to Radiation-Induced Tumor Vaccination. <i>Frontiers in Immunology</i> , 2017 , 8, 229	8.4	111
78	Therapeutic effect of local Interleukin-15 with radiotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 158-158	2.2	
77	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge Napoli, December 5th 2015 2016 , 4,		78
76	Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. <i>Journal of Translational Medicine</i> , 2016 , 14, 65	8.5	8
75	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials 2016 , 4, 15		47
74	Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking? 2016 , 4, 29		50
73	Subverting misconceptions about radiation therapy. <i>Nature Immunology</i> , 2016 , 17, 345	19.1	2
72	Local radiotherapy and GM-CSF in metastatic cancer: lessons from a proof of principle trial. <i>OncolImmunology</i> , 2016 , 00-00	7.2	1
71	Quality of Life in Women Undergoing Breast Irradiation in a Randomized, Controlled Clinical Trial Evaluating Different Tumor Bed Boost Fractionations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 579-89	4	5
70	Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy. <i>Clinical Breast Cancer</i> , 2016 , 16, 113-22.e1	3	43
69	Predicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure. <i>Frontiers in Oncology</i> , 2016 , 6, 168	5.3	34
68	Prospective Randomized Trial of Prone Accelerated Intensity Modulated Breast Radiation Therapy With a Daily Versus Weekly Boost to the Tumor Bed. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 571-8	4	16
67	Radiotherapy: Changing the Game in Immunotherapy. <i>Trends in Cancer</i> , 2016 , 2, 286-294	12.5	200
66	Does Heavy Ion Therapy Work Through the Immune System?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 934-936	4	49
65	Current clinical trials testing the combination of immunotherapy with radiotherapy 2016 , 4, 51		262

64	Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. <i>Immunity</i> , 2016 , 45, 931-943	32.3	376
63	Preplanning prediction of the left anterior descending artery maximum dose based on patient, dosimetric, and treatment planning parameters. <i>Advances in Radiation Oncology</i> , 2016 , 1, 373-381	3.3	8
62	Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. <i>Lancet Oncology, The</i> , 2015 , 16, 795-803	21.7	409
61	Society of Chairs of Academic Radiation Oncology Programs-Endorsed Radiation Oncology Department Review Process. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 92, 536-94		
60	Treatment of Non-Melanomatous Skin Cancer with Radiotherapy. <i>Current Dermatology Reports</i> , 2015 , 4, 187-194	1.5	
59	In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. <i>Vaccine</i> , 2015 , 33, 7415-7422	4.1	116
58	Radiotherapy for extensive stage small-cell lung cancer. <i>Lancet, The</i> , 2015 , 385, 1290-1	4.0	2
57	Locally advanced breast cancer - strategies for developing nations. <i>Frontiers in Oncology</i> , 2015 , 5, 89	5.3	12
56	TGFβs a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. <i>Cancer Research</i> , 2015 , 75, 2232-42	10.1	331
55	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. <i>Science</i> , 2015 , 350, 1079-84	33.3	1689
54	Role of Local Radiation Therapy in Cancer Immunotherapy. <i>JAMA Oncology</i> , 2015 , 1, 1325-32	13.4	401
53	Myeloid-derived cells in tumors: effects of radiation. <i>Seminars in Radiation Oncology</i> , 2015 , 25, 18-27	5.5	91
52	Seminars in Radiation Oncology. Introduction. <i>Seminars in Radiation Oncology</i> , 2015 , 25, 1-3	5.5	3
51	Current clinical trials testing combinations of immunotherapy and radiation. <i>Seminars in Radiation Oncology</i> , 2015 , 25, 54-64	5.5	103
50	Pro-oncogenic cytokines and growth factors are differentially expressed in the post-surgical wound fluid from malignant compared to benign breast lesions. <i>SpringerPlus</i> , 2015 , 4, 483		6
49	Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes. <i>Journal of Contemporary Brachytherapy</i> , 2015 , 7, 445-52	1.9	12
48	Impact of maternal death from female cancers on child mortality.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6591-6591	2.2	
47	Is classical stereotactic radiotherapy the optimal partner for immunotherapy?. <i>Oncology</i> , 2015 , 29, 340, 347, 387	1.8	4

46	Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 11-7	4	15
45	Prone breast intensity modulated radiation therapy: 5-year results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 899-906	4	32
44	Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade 2014 , 2,		5
43	Risk and risk reduction of major coronary events associated with contemporary breast radiotherapy. <i>JAMA Internal Medicine</i> , 2014 , 174, 158-60	11.5	35
42	Is tumor (R)ejection by the immune system the "5th R" of radiobiology?. <i>OncolImmunology</i> , 2014 , 3, e28133		38
41	Combinations of immunotherapy and radiation in cancer therapy. <i>Frontiers in Oncology</i> , 2014 , 4, 325	5.3	164
40	Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3204-5	2.2	7
39	Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. <i>OncolImmunology</i> , 2014 , 3, e28518	7.2	309
38	Burnout in United States academic chairs of radiation oncology programs. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 363-8	4	18
37	Combining radiotherapy and cancer immunotherapy: a paradigm shift. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 256-65	9.7	685
36	An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. <i>Cancer Immunology Research</i> , 2013 , 1, 365-72	12.5	507
35	Positioning during radiotherapy for breast cancer--reply. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 137	27.4	2
34	The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. <i>OncolImmunology</i> , 2013 , 2, e25997	7.2	25
33	Prone hypofractionated whole-breast radiotherapy without a boost to the tumor bed: comparable toxicity of IMRT versus a 3D conformal technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, e415-23	4	36
32	Prospective assessment of optimal individual position (prone versus supine) for breast radiotherapy: volumetric and dosimetric correlations in 100 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, 902-9	4	99
31	Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 6668-78	12.9	114
30	Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 6748-57	12.9	146
29	Global breast cancer: the lessons to bring home. <i>International Journal of Breast Cancer</i> , 2012 , 2012, 249503		14

28	Radiation as an immunological adjuvant: current evidence on dose and fractionation. <i>Frontiers in Oncology</i> , 2012 , 2, 153	5.3	214
27	Prone vs supine positioning for breast cancer radiotherapy. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 861-3	27.4	115
26	Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. <i>Journal of Clinical Investigation</i> , 2012 , 122, 3718-30	15.9	143
25	TGF β inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. <i>Clinical Cancer Research</i> , 2011 , 17, 6754-65	12.9	178
24	Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. <i>Clinical Cancer Research</i> , 2010 , 16, 681-90	12.9	143
23	More radiotherapy for radiation-induced second malignancies?. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 851-2	4.4	
22	Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 723-32	4.4	57
21	Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. <i>Clinical Cancer Research</i> , 2009 , 15, 597-606	12.9	72
20	Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. <i>Clinical Cancer Research</i> , 2009 , 15, 5379-88	12.9	1042
19	Systemic effects of local radiotherapy. <i>Lancet Oncology, The</i> , 2009 , 10, 718-26	21.7	645
18	Local control by radiotherapy: is that all there is?. <i>Breast Cancer Research</i> , 2008 , 10, 215	8.3	39
17	Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. <i>Journal of Immunology</i> , 2008 , 181, 3099-107	5.3	466
16	Effects of chemoradiation on tumor-host interactions: the immunologic side. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1562-3; author reply 1563	2.2	31
15	Accelerated intensity-modulated radiotherapy to breast in prone position: dosimetric results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 68, 1251-9	4	45
14	Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2236-42	2.2	133
13	Sensors of ionizing radiation effects on the immunological microenvironment of cancer. <i>International Journal of Radiation Biology</i> , 2007 , 83, 819-25	2.9	88
12	External-beam-based partial breast irradiation. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 326-7		5
11	The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. <i>Clinical Cancer Research</i> , 2006 , 12, 4730-7	12.9	120

10	Combining radiotherapy and immunotherapy: a revived partnership. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, 655-66	4	265
9	External-beam partial-breast irradiation. <i>Seminars in Radiation Oncology</i> , 2005 , 15, 92-9	5.5	58
8	Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 728-34	12.9	622
7	Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 58, 862-70	4	893
6	Prone accelerated partial breast irradiation after breast-conserving surgery: preliminary clinical results and dose-volume histogram analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 60, 493-504	4	203
5	Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 864-70	2.2	95
4	Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 52, 397-405	4	26
3	T1 stage breast cancer: adjuvant hypofractionated conformal radiation therapy to tumor bed in selected postmenopausal breast cancer patients--pilot feasibility study. <i>Radiology</i> , 2002 , 222, 171-8	20.5	99
2	BRCA1/2 germline mutations: a marker for radioresistance or radiosensitivity?. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1159-60	2.2	13
1	Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997 , 39, 1059-68	4	43